Onco-Genomas Brasil: Mapping Breast and Prostate Cancer in the Brazilian Public Health System

Recruiting

Interventions: Diagnostic Test: whole exome and whole genome sequencing analysis

Brief Summary: This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program, called Genomas Brasil, as well as to collect data on the population's ancestry.

Detailed Description: In Brazil, the most frequent types of neoplasm are prostate cancer in men and breast cancer in women. Understanding the molecular variants in tumors, which result from mutations and variants that occur during carcinogenesis, can affect treatment response and disease prognosis and is an important target of oncology research. Detecting hereditary genetic syndromes also helps in oncological follow-up, allowing prediction of the risk of new neoplasms. This project aims to perform complete sequencing of the somatic (tumor) and germline exomes during clinical investigation of cancer patients treated through the Brazilian Unified Health System to generate genomic and phenotypic data for the Brazilian Ministry of Health's National Precision Genomics and Health Program, called Genomas Brasil, as well as to collect data on the population's ancestry.

Recruitment & Eligibility

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Arm && Interventions

Group	Intervention	Description
Prostate cancer	whole exome and whole genome sequencing analysis	137 patients with metastatic prostate cancer
Breast cancer	whole exome and whole genome sequencing analysis	745 patients with HER2-positive and triple-negative breast cancer who underwent neoadjuvant therapy followed by breast surgery.

Primary Outcome Measures

Name	Time	Method
To characterize complete somatic and germline exomes/genomes in a Brazilian population	12 months	Mutations in the somatic and germline exomes/genomes of women with HER2-positive and triple-negative breast cancer and of men with metastatic prostate cancer will be described

Secondary Outcome Measures

Name	Time	Method
To identify genetic variants predictive of response to treatments	12 months	Mutations in the somatic and germline exomes/genomes will be correlated to response to treatments
To identify genetic variants related to tumor prognosis	12 months	Mutations in the somatic and germline exomes/genomes will be correlated to clinical outcomes
Number of patients with mutations in cancer-predisposing genes	12 months	Identify mutations in germline exomes/genomes related to hereditary cancer syndromes

Locations (19): Hospital do Câncer do Maranhão
🇧🇷
São Luís, Maranhão, Brazil
Hospital das Clínicas
🇧🇷
Belo Horizonte, Minas Gerais, Brazil
Hospital Universitário João de Barros Barreto
🇧🇷
Belém, Pará, Brazil
Hospital Universitário Cassiano Antônio de Moraes
🇧🇷
Vitória, Brazil
Hospital Calixto Midlej Filho/ Santa Casa de Itabuna
🇧🇷
Itabuna, Bahia, Brazil
Hospital Santa Rita de Cássia - AFECC
🇧🇷
Vitória, Espírito Santo, Brazil
Hospital de Clínicas de Porto Alegre
🇧🇷
Porto Alegre, Brazil
Hospital Fêmina
🇧🇷
Porto Alegre, Brazil
Hospital São Camilo
🇧🇷
São Paulo, Brazil
Liga Norte Riograndense Contra o Câncer
🇧🇷
Natal, Rio Grande Do Norte, Brazil
Hospital Universitário Maria Aparecida Pedrossian
🇧🇷
Campo Grande, Brazil
Hospital São Lucas da PUCRS
🇧🇷
Porto Alegre, Brazil
Grupo Hospitalar Conceição
🇧🇷
Porto Alegre, Brazil
Hospital Universitário Getúlio Vargas
🇧🇷
Manaus, Amazonas, Brazil
Hospital da Santa Casa de Misericórdia
🇧🇷
Belo Horizonte, Minas Gerais, Brazil
Hospital Escola da Universidade Federal de Pelotas
🇧🇷
Pelotas, Rio Grande Do Sul, Brazil
Hospital Araújo Jorge
🇧🇷
Goiânia, Brazil
Hospital do Amor
🇧🇷
Barretos, São Paulo, Brazil
Hospital do Câncer/União Oeste Paranaense de Estudo e Combate ao Câncer
🇧🇷
Cascavel, Paraná, Brazil